Linked Life Data

19738422

Source:http://linkedlifedata.com/resource/pubmed/id/19738422

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2009-11-6
pubmed:abstractText
One of the major difficulties in the treatment of epithelial ovarian cancer (EOC) is the high rate of recurrent disease. This is thought to be due to the survival of a population of chemo-resistant cells within the tumor, the ovarian cancer stem cells (OCSCs), that are able to regenerate the tumor following chemotherapy. Therefore, the identification of a compund that can target the OCSCs is one of the main steps in improving overall survival of ovarian cancer patients. The objective of this study was to determine the effect of N-t-boc-Daidzein, a novel daidzain derivative, on OCSCs. The efficacy of this compound was evaluated in OCSC and mature ovarian cancer cell (mOCC) lines isolated from malignant ovarian cancer asicites. Cells were treated with increasing concentrations of N-t-boc-Daidzein (0.003-10 microM) and cell growth was monitored by "real time in vitro micro-imaging" using the IncuCyte system. Cell viability was measured using the CellTiter 96 Assay. Apoptosis was determined by Caspase-Glo 3/7, 8 and 9 assays. The components of the apoptotic cascade were characterized by western blot analysis. N-t-boc-Daidzein was able to significantly inhibit cell growth and decrease cell viability of OCSC as well as mOCC cells in a dose and time dependent maner. This effect was due to the induction of apoptosis, which is characterized by caspase activation, XIAP and AKT degradation, and mitochondrial depolarization. This study describes a novel compound that can target the OCSCs. These findings may provide vital aide in improving overall survival in patients with EOC.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1555-8576
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1747-53
pubmed:dateRevised
2011-5-30
pubmed:meshHeading
pubmed-meshheading:19738422-Apoptosis, pubmed-meshheading:19738422-Blotting, Western, pubmed-meshheading:19738422-Carbamates, pubmed-meshheading:19738422-Caspases, pubmed-meshheading:19738422-Cell Line, Tumor, pubmed-meshheading:19738422-Cell Proliferation, pubmed-meshheading:19738422-Cell Survival, pubmed-meshheading:19738422-Chromones, pubmed-meshheading:19738422-Dose-Response Relationship, Drug, pubmed-meshheading:19738422-Epithelial Cells, pubmed-meshheading:19738422-Female, pubmed-meshheading:19738422-Flow Cytometry, pubmed-meshheading:19738422-Humans, pubmed-meshheading:19738422-Isoflavones, pubmed-meshheading:19738422-Mitochondria, pubmed-meshheading:19738422-Models, Biological, pubmed-meshheading:19738422-Neoplastic Stem Cells, pubmed-meshheading:19738422-Oncogene Protein v-akt, pubmed-meshheading:19738422-Ovarian Neoplasms, pubmed-meshheading:19738422-Time Factors, pubmed-meshheading:19738422-X-Linked Inhibitor of Apoptosis Protein
pubmed:year
2009
pubmed:articleTitle
7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: a novel compound capable of inducing cell death in epithelial ovarian cancer stem cells.
pubmed:affiliation
Department of Obstetrics and Gynecology and Reproductive Science, Yale University School of Medicine, New Haven, CT 06520, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural